BPC-157 FAQ: answers from the record, cited

BPC-157 side effects in the research literature

BPC-157 side effects are not well characterized in humans, because the human dataset is three small pilots and none was designed to map a side-effect profile. The 2-person IV safety pilot reported no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[9]; the 12-patient intravesical pilot reported no adverse events ^[11]. Those are reassuring within a tiny dataset, not a safety profile.

The candid summary is the one the 2025 narrative review reaches: reported safety is reassuring within the small human dataset and the animal work, but the absence of long-term, large-N human safety data means the safety profile is genuinely unknown ^[10]. A frequently noted theoretical consideration is that BPC-157 is pro-angiogenic in models ^[3] — the literature flags this without establishing any causal harm. The honest answer foregrounds the gap rather than the reassurance.